Japan Orders More Relenza Flu Vaccine From GSK
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare has ordered more Relenza (zanamivir) flu vaccine from British drug maker GlaxoSmithKline. For this flu season, the Ministry has prepared the vaccine for 3 million people, which is one-third of Tamiflu (oseltamivir phosphate) stockpiles. However, among the flu cases reported nationwide, 44.5 percent are infected with H1N1 type virus, which is resistant to Tamiflu. Worried about a possible shortage of Relenza, the Ministry requested additional vaccine from GSK. The drug maker has asked drug wholesalers in Japan to adjust shipping based on inventory conditions, and MHLW has cautioned medical facilities to avoid large orders of the drug. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.